The intensive care medicine research agenda in nutrition and metabolism

The value of early initiation of EN is supported by physiologic data. Over the first week of ICU admission, most critically ill patients experience the non-nutritional benefits of EN by virtue of the gastrointestinal responses [maintaining gut integrity, supporting the diversity of the microbiome, and sustaining gut-associated lymphoid tissue (GALT) and secretory IgA production], immune responses [sustaining mucosa-associated lymphoid tissue (MALT) at distant sites, stimulating Th2 anti-inflammatory lymphocytes and T-regulatory cells], and metabolic responses [increasing incretin release, and reducing generation of advanced glycation end products (AGEs)] (Supplementary References). Meta-analyses of randomized controlled trials (RCTs) demonstrate that early EN is associated with reduction in mortality and infections compared to withholding early EN, although the included individual clinical trials are heterogeneous and not adequately powered [5]. Additionally, the definition of early nutrition remains arbitrary and has ranged from 3 to 7 days in different interventional studies. Nevertheless, the notion that EE must be met universally in all ICU patients during the acute phase of critical illness has been challenged. Indeed, a number of trials in general ICU patients and in selected populations (acute respiratory failure, acute lung injury, refeeding syndrome) show that restricted feeding strategies described as “permissive or trophic” during the early phase of critical illness result in similar outcomes compared with standard caloric intake (Table 1) [6‐10]. However, “standard” caloric intake in these trials met only 70–80% of EE. The protein intakes also differed between the study arms in most studies [6, 7], but not all [8]. So it remains uncertain whether the provision of energy to fully match EE has clinical benefit.

Along with the lack of benefit of early aggressive EN, the use of supplemental PN in the first week to achieve caloric targets for all patients has now been challenged. The EPaNIC study, conducted in critically ill adults in whom caloric targets could not be met by EN alone, showed that late initiation of PN (i.e., after a week of critical illness) was associated with faster recovery and fewer complications, as compared with early initiation [11]. Interestingly, the similarly designed PEPaNIC trial in critically ill children showed similar results [12]. The Early PN trial found that early PN (i.e., within the first hours of admission in ICU) to critically ill adults with relative contraindications to early EN was not associated with a significant clinical benefit [13]. Another study enrolled patients who received less than 60% of EE from EN at ICU day 3 and found that supplemental PN was associated with a decrease of late infections compared to EN alone [14]. Of note, common infections, including pneumonia and bloodstream infections, did not decrease [14]. While these studies are somewhat conflicting, it would appear that there is no benefit in providing nutrition parenterally early in the ICU stay.

The underlying mechanisms and potential consequences of an increased provision of nutrients during the early phase of critical illness are currently investigated. A pre-planned secondary analysis of 600 patients included in the EPaNIC trial, with prospective assessment of functional weakness, revealed that tolerating a substantial macronutrient deficit during the first week of critical illness reduced ICU-acquired weakness (ICU-AW). In addition, muscle biopsies indicated that activation of autophagy might explain the protective effect on weakness of delaying PN delivery [15]. Hyperglycemia during feeding may occur since the endogenous production of glucose cannot be fully inhibited by exogenous caloric supply [3]. Nutrient delivery may lead to the development of refeeding syndrome or may counteract potentially adaptive early anorectic response of severe illness, particularly in severely ill patients, identified by high “nutritional risk” as discussed below. Irrespective of the underlying mechanisms, the optimal amount of calories and proteins in the early phase of critical illness remains unknown.

The CALORIES trial was a pragmatic RCT that compared early EN to early PN for the first 5 days in an unselected critically ill population. The majority of patients in both arms did not reach EE targets and no difference on short-term outcome was found [16]. A recent meta-analysis that included the results of the CALORIES trial comparing EN to PN found no effect on overall mortality [17]. However, EN was associated with lower infective complications and shorter ICU length of stay (LOS) [17].

It has been generally accepted that a small percentage of patients, those at highest nutritional risk, may require the nutritional benefits of therapy where full macro- and micronutrient provision maximizes protein synthesis, supports lean body mass, and corrects nutrient deficiencies. Hence, there has been increasing work to define nutritional risk assessment in nutrition therapy [18]. The NUTRIC (The Nutrition Risk in Critically ill) score was proposed to identify those who will benefit the most from nutrition therapy or be harmed the most by ongoing inattention to nutrition. The clinical utility of this score has been examined in three multi-institutional databases. These studies demonstrate that patients with high NUTRIC scores have reduced mortality with increased nutrition intake compared to patients with low NUTRIC scores where no such relationship between intake and mortality exists [18, 19]. Of note, the variables included in this score mainly reflect the severity of disease and are not direct measures of nutritional status. A post hoc analysis of the PermiT trial showed that permissive underfeeding was associated with similar mortality compared with standard feeding in patients with high and low nutritional risk as assessed by the NUTRIC score and several other nutritional risk tools [20]. Other scores have also been developed, such as the Nutrition Risk Screening-2002 (NRS-2002) score and the Patient- And Nutrition-Derived Outcome Risk Assessment Score (PANDORA); the latter has yet to be validated in the critically ill population [21, 22]. The role of nutritional assessment using an objective measurement of body composition or more specifically muscle mass (using CT, ultrasound, or bioelectric impedance) requires further study (Supplementary References). Although these parameters identify increased risk of death, it is unclear if these are modifiable by nutrition or if they just reflect disease severity.

The uncertainty about the optimal approach for nutritional assessment is further complicated by the controversy regarding whether patients with severe undernutrition would benefit or alternatively suffer from high energy and protein intakes. In patients with hypophosphatemia within 72 h of initiation of nutrition, restricted versus standard caloric intake resulted in no difference in the primary endpoint of the number of days alive after ICU discharge, but with more patients alive at day 60 [23]. Post hoc analysis of the PermiT trial suggested that patients with low prealbumin levels might have better outcomes with restricted calories [20]. Post hoc analysis of the EPaNIC trial showed that the beneficial effect of a delay in the initiation of PN was generalized across different strata of severity of illness including those who were most severely ill [24]. Interestingly, the PEPaNIC trial showed that early PN provoked more harm in children at increased nutritional risk according to their Screening Tool for Risk on Nutritional Status and Growth (STRONGkids) score [12].

Another aspect of nutritional assessment is how to differentiate the acute (catabolic) phase and the post-acute (anabolic) phase. There is a need for a dynamic marker to identify patients “readiness for enhanced feeding”. Such a marker would allow an adaptation of the nutritional strategy to the clinical evolution based on endocrinological or metabolic signals rather than starting enhanced energy/protein intake at a predefined number of days.

The role of GRV measurement to monitor tolerance of patients on EN has been challenged. Although GRVs are generally considered to indicate gastric emptying rate, volumes aspirated are also affected by the rate of feed administration, the technique of aspiration, gastric secretion, and duodeno-gastric reflux. Increasing the limit of monitored GRV from 200 to 500 ml (REGANE study) or adopting a no routine monitoring of GRV strategy (NUTRIREA1 study) among adults requiring mechanical ventilation did not increase pneumonia [25, 26]. However, these studies included predominately patients admitted for medical (as opposed to surgical) reasons and were underpowered to assess the impact on other clinical outcomes. In one study, a 24-h total GRV of greater than 250 ml was shown to predict slow gastric emptying, but the sensitivity and negative predictive value were modest [27].

The use of immune-modulating macronutrients (e.g., glutamine, arginine, and omega-3 fatty acids) and micronutrients (e.g., antioxidant vitamins A, C, and E and the minerals selenium and zinc) used alone (pharmaconutrition) or in combination (immunonutrition) to enrich EN or PN and improve outcomes of ICU patients has been challenged in a number of RCTs [28]. The REDOXS trial showed an increase in mortality with high doses of enteral and parenteral glutamine (0.6 g/kg per day) [29]. The OMEGA trial showed that enteral supplementation of n-3 fatty acids, γ-linolenic acid, and antioxidants in patients with acute lung injury did not improve the primary endpoint of ventilator-free days or other clinical outcomes and might be harmful [30]. In the MetaPlus study, high-protein EN enriched with glutamine, omega-3 fatty acids, selenium, and antioxidants did not reduce infectious complications or improve other clinical endpoints when compared to standard high-protein EN and may have been harmful as suggested by an increased adjusted 6-month mortality [31]. A recent meta-analysis showed that enteral glutamine supplementation does not confer clinical benefit in critically ill patients [32]. However, in severe burn patients, enteral glutamine supplementation was associated with reduction in hospital mortality and stay [32].

The danger of providing arginine in the setting of sepsis has been challenged, as multiple studies in septic patients showed no adverse hemodynamic changes in response to intravenous arginine infusion [33]. The use of arginine/fish oil formulas may still be beneficial in elective surgical patients, as its use has been shown in four recent meta-analyses to reduce infection and hospital LOS and improve other clinical outcomes (Supplementary References). In severe acute pancreatitis, three small studies in immune-modulating nutrition of varying components showed improved outcomes, but the small numbers enrolled were such that only one reached significance and a meta-analysis was negative (Supplementary References). This last group of patients (severe acute pancreatitis) should be studied further before discounting immune-modulating nutrition across the board. Important questions regarding immune-modulating nutrition remain (Table 1).

The survival benefit of tight glucose control (TGC) (target 4.4–6.1 mmol/L) observed in an RCT of predominantly (cardiac) surgical patients and an RCT of medical ICU patients [34, 35] could not be reproduced in other RCTs [36]. The largest trial, NICE-SUGAR, showed increased 90-day mortality with TGC compared to a target of less than 10 mmol/L [37]. The observed differences in outcome may be related to different targets achieved, different blood glucose analyzing methodology, or the difference in the amount and route of early nutritional intake between the Leuven as compared to the other trials [36, 38]. After 15 years of intense research in this field, a few assertions are widely accepted: (1) there are three domains of dysglycemia (severe hyperglycemia, moderate hypoglycemia, and high glycemic variability) which are individually and synergistically associated with poor vital outcome; (2) blood glucose control is demanding, difficult to perform, and requires technological improvements in monitoring and therapeutic modalities including automated algorithms and new agents such as long-acting insulin or glucagon-like peptide-1 (GLP-1) agonists; (3) the optimal target could differ over time and according to the pre-existence of diabetes and its control. A study found that markers of inflammation, endothelial injury, and coagulation activation were attenuated in the patients with stress hyperglycemia without diabetes but not in diabetics, suggesting different underlying pathophysiology. In a large observational study, reduced mortality was observed with blood glucose between 80 and 140 mg/dl in non-diabetic patients and 110–180 mg/dl in diabetic patients (Supplementary References). These hypothesis-generating findings are yet to be examined in RCTs.

Indirect calorimetry is considered the gold standard in measuring EE in clinical settings [39] and is recommended, when available, by clinical practice guidelines, although it is acknowledged that the evidence on which this premise is based is limited [5, 40]. Indirect calorimetry measurements of EE are generally performed during 1–2 h per day and under controlled conditions and therefore do not account for the variation of EE during 24 h. Nevertheless, measuring EE might have a role in preventing overfeeding. Predictive equations are often used instead of direct EE measurement but may over- or underestimate EE and do not account for the variation of EE during critical illness over time [3]. As in clinical practice, most major studies including targeted feeding in the design rely on these predicted values of EE. A more fundamental question is whether calories delivered to patients during the acute phase of their critical illness should match measured or estimated EE despite ongoing endogenous nutrient release, which is not suppressed by feeding and is unmeasurable [41]. Other important questions remain on to how to assess nutritional risk and how to to determine which patient groups benefit from specific nutritional interventions and which do not or experience harm (Table 2)

The approach of continuous feeding has been challenged as being unphysiologic [42]. In animal models and in healthy volunteers, data suggest that protein synthesis is significantly greater after the consumption of a single bolus dose of whey protein than when the whey protein was given as small-pulsed drinks or as a continuous infusion [42‐44]. Intermittent feeding may also have greater anabolic response, increased gastric contractility and emptying, as well as less diarrhea and better absorption owing to slowing of intestinal transit from increased peptide YY release [45, 46]. However, clinical data supporting this practice are awaited.

It remains unclear what constitutes an optimal protein “dose” to facilitate recovery of nutritionally high-risk patients. Current recommendations are based on very limited evidence. In one trial, a daily intravenous supplement of standard amino acids did not alter the duration of renal dysfunction, and functional outcome at 90 days was unaffected by the large difference in dose of amino acids (0.5–1 kg over 1 week) [47]. In another study, the administration of amino acids at either 0.8 or 1.2 g/kg in patients receiving PN did not result in a difference in the primary endpoint of handgrip at ICU discharge, although it resulted in slight improvements in other functional outcomes and in nitrogen balance [48]. The interpretation of these improvements was somewhat complicated by the higher mortality (potentially competing with weakness) in the patients receiving more amino acids [49].

Another issue to consider is whether there is any interrelationship between calorie and protein “dose”. There is evidence to suggest that if a basal amount of protein is provided, varying the percentage of goal calories delivered may not change outcome. In the PermiT trial [8] and other studies [50], restricting calories did not change outcome compared to full feeds when protein provision was equal between groups. On the other hand, data from the International Nutrition Survey 2013 showed that achieving at least 80% of prescribed protein intake (but not energy intake) was associated with increased survival in ICU patients [51]. Another study showed increased survival with achievement of protein intake of 1.2 g/kg body weight when patients were not overfed with energy (more than 110% of measured EE) [52]. An earlier small RCT showed that higher protein delivery at 1.4 gm/kg/day (and reduced calories, 12 kcal/kg) led to better outcome (reduced SOFA score at 48 h) than lower protein doses at 0.76 gm/kg/day (and reduced calories, 14 kcal/kg) [53].

Not all proteins are equivalent in their ability to stimulate protein synthesis; whey protein (high in leucine) may increase muscle synthesis compared to soy or casein protein [42]. An RCT in obese older adults showed that a high whey protein-, leucine-, and vitamin D-enriched supplement compared with isocaloric control preserves appendicular muscle mass during hypocaloric feeding and resistance exercise program [54]. The implications for critically ill patients are unknown and require further study.

While many different combinations of amino acids are theoretically possible, it remains unclear whether these combinations should mimic “normal” intake or be aimed at inducing metabolism or supporting host defense. In contrast to lipids or glucose, an individual amino acid given in excess of demands cannot be simply stored and needs to be metabolized, thereby consuming other amino acids [15, 55].

Long-term functional recovery of some ICU patients is markedly impaired, e.g., patients with severe ARDS only achieve 76% of a reference value on 6-min walk test for up to 5 years [56]. The relationship between ICU-acquired weakness (ICU-AW) and delayed functional recovery is only partially established and it is unclear if loss of myofiber mass as compared to loss of myofiber integrity and quality contributes more to the loss of muscle force [15, 57]. Rates of muscle atrophy and changes in muscle architecture have been quantified and are associated with poor clinical outcomes, although the role of assessment of skeletal muscle mass using computed tomography imaging and ultrasonography and assessment of fat-free mass using bioelectrical impedance analysis remain to be established [58, 59]. Nevertheless ICU-AW is associated with a longer hospital stay, decreased likelihood to go home after hospital discharge, and reduced long-term survival [60].

While it is evident that rehabilitation should play an important role, from other areas of research (sports, elderly), it is likely that the combination of protein and exercise will improve physical performance (Fig. 2) [61, 62]. Surprisingly, withholding PN in patients who received protocolized physiotherapy and passive or active bedcycling reduced the incidence of ICU-AW and enhanced recovery in a 600-patient substudy of the EPaNIC trial [15]. This underscores the fact that general principles that apply in other physiologic conditions may not apply to very early ICU nutrition.

While the benefit of early enhanced feeding has long been overestimated, the importance of prolonged often unnoticed and unintentional underfeeding is under addressed, particularly after ICU discharge to the conventional ward [63]. This deserves much more attention, as patients in this phase of recovery may be more likely to experience benefit by enhanced nutrition possibly in combination with physical exercise.

A meta-analysis of 15 RCTs showed that small intestinal feeding compared to gastric feeding improved nutritional intake and reduced the incidence of ICU-acquired pneumonia but did not affect other clinically important outcomes [64]. However, the indications for small intestinal feeding (when? for whom?) in the ICU remain unclear.

Development of novel motility agents beyond erythromycin and metoclopramide remains an area of active investigation. Use of currently available agents is limited by the fear of adverse effects and tachyphylaxis as their efficacy decreases over time (4–5 days). A novel motilin agonist without antibiotic or cardiac effects has recently been shown to accelerate gastric emptying in critically ill patients (Supplementary References). However, the clinical benefits of gastric emptying acceleration and delivery of more nutrition still need to be proven and compared to post-pyloric feeding tubes.

There is considerable research being conducted in different aspects of nutrition therapy in critically ill patients. Table 3 summarizes open RCTs registered on clinicaltrials.gov as examples of ongoing work. The panel identified the following studies as the top 10 trials/studies for the next 10 years using the methodology outlined in the online supplement (Table 4). In brief, the panel members suggested candidate topics, then rated each one using a grading system (0–4). Potential studies were ranked on the basis of average score. The following received the highest priory scores.

In conclusion, recent trials have answered important questions but also highlighted or revealed several uncertainties in many aspects of critical care nutrition and metabolism. We ranked the top 10 studies for the next 10 years, with the prospect that different nutritional interventions targeted to the appropriate patient population will be examined for their effect on facilitating recovery and improving survival in adequately powered and properly designed studies, probably in conjunction with mobilization. Undoubtedly, the next 10 years are likely to be an exciting era for nutrition and metabolism.